secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K/A
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001193125-23-003537
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies: CEO salary $600K, President $565K; equity grants of 1.1M and 790K options
--------------------------------------------------------------------------------

- Sean Nolan appointed CEO effective Dec 16, 2022; base salary $600K, annual target bonus 60% of base.
- Nolan receives option for 1,106,131 shares; 25% vests Dec 16, 2023, remainder monthly over 36 months.
- Sukumar Nagendran appointed President & Head of R&D; base $565K, bonus target 50%, option for 790,093 shares with same vesting.
- Severance: Nolan gets 18 months salary + 150% target bonus; Nagendran 15 months + 100% target bonus upon qualifying termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523003537/0001193125-23-003537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523003537/d410825d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-003537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer